These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 23835667)

  • 21. Cystatin C levels are associated with the prognosis of systolic heart failure patients.
    Gao C; Zhong L; Gao Y; Li X; Zhang M; Wei S
    Arch Cardiovasc Dis; 2011 Nov; 104(11):565-71. PubMed ID: 22117908
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Remnant lipoproteins play an important role of in-stent restenosis in type 2 diabetes undergoing percutaneous coronary intervention: a single-centre observational cohort study.
    Qin Z; Zhou K; Li YP; Wang JL; Cheng WJ; Hu CP; Shi C; He H; Zhou YJ
    Cardiovasc Diabetol; 2019 Jan; 18(1):11. PubMed ID: 30691501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blood Pressure Levels at the Time of Percutaneous Coronary Revascularization and Risk of Coronary In-Stent Restenosis.
    Tocci G; Barbato E; Coluccia R; Modestino A; Pagliaro B; Mastromarino V; Giovannelli F; Berni A; Volpe M
    Am J Hypertens; 2016 Apr; 29(4):509-18. PubMed ID: 26271109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preprocedural high-sensitivity C-reactive protein predicts death or myocardial infarction but not target vessel revascularization or stent thrombosis after percutaneous coronary intervention.
    Delhaye C; Sudre A; Lemesle G; Maréchaux S; Broucqsault D; Hennache B; Bauters C; Lablanche JM
    Cardiovasc Revasc Med; 2009; 10(3):144-50. PubMed ID: 19595394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Relationship Between Lymphocyte-to-Monocyte Ratio and Bare-Metal Stent In-Stent Restenosis in Patients With Stable Coronary Artery Disease.
    Murat SN; Yarlioglues M; Celik IE; Kurtul A; Duran M; Kilic A; Oksuz F
    Clin Appl Thromb Hemost; 2017 Apr; 23(3):235-240. PubMed ID: 26759373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of hyperuricemia on clinical outcomes after percutaneous coronary intervention for in-stent restenosis.
    Joo HJ; Jeong HS; Kook H; Lee SH; Park JH; Hong SJ; Yu CW; Lim DS
    BMC Cardiovasc Disord; 2018 Jun; 18(1):114. PubMed ID: 29890945
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Significant association of coronary stent fracture with in-stent restenosis in sirolimus-eluting stents.
    Kim JS; Lee SY; Lee JM; Yoon YW; Ahn CM; Kim MH; Min PK; Ko YG; Hong BK; Choi D; Kwon HM; Jang Y; Shim WH
    Coron Artery Dis; 2009 Jan; 20(1):59-63. PubMed ID: 19008765
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Levels of plasma Quaking and cyclooxygenase-2 predict in-stent restenosis in patients with coronary artery disease after percutaneous coronary intervention.
    Wang P; Kuang Y; Liu Y; Zhang Y; Gao H; Ma Q
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Jun; 47(6):739-747. PubMed ID: 35837773
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relation of soft plaque and elevated preprocedural high-sensitivity C-reactive protein levels to incidence of in-stent restenosis after successful coronary artery stenting.
    Hong YJ; Jeong MH; Lim SY; Lee SR; Hong SN; Kim KH; Sohn IS; Park HW; Kim JH; Kim W; Ahn Y; Cho JG; Park JC; Kang JC
    Am J Cardiol; 2006 Aug; 98(3):341-5. PubMed ID: 16860020
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In-stent restenosis-prone coronary plaque composition: A retrospective virtual histology-intravascular ultrasound study.
    Seo DJ; Kim YK; Seo YH; Song IG; Kim KH; Kwon TG; Park HW; Bae JH
    Cardiol J; 2018; 25(1):7-13. PubMed ID: 29064537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optical coherence tomography-based predictors for creatine kinase-myocardial band elevation after elective percutaneous coronary intervention for in-stent restenosis.
    Lee SY; Hong MK; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Jang Y
    Catheter Cardiovasc Interv; 2015 Mar; 85(4):564-72. PubMed ID: 25158217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An increase of VEGF plasma levels is associated with restenosis of drug-eluting stents.
    Katsaros KM; Kastl SP; Krychtiuk KA; Hutter R; Zorn G; Maurer G; Huber K; Wojta J; Christ G; Speidl WS
    EuroIntervention; 2014 Jun; 10(2):224-30. PubMed ID: 24168783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and pathological characteristics of homogeneous and nonhomogeneous tissue of in-stent restenosis visualized by optical coherence tomography.
    Itoh T; Fusazaki T; Kimura T; Oikawa H; Sasou S; Ishikawa Y; Goto I; Komuro K; Nakajima S; Koeda Y; Kaneko K; Nishiyama O; Nakamura M; Morino Y
    Coron Artery Dis; 2015 May; 26(3):201-11. PubMed ID: 25714072
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of plasma C-reactive protein in predicting in-stent restenosis in patients with stable angina after coronary stenting.
    Xu YL; Li JJ; Xu B; Zhu CG; Yang YJ; Chen JL; Qiao SB; Yuan JQ; Qin XW; Ma WH; Yao M; Liu HB; Wu YJ; Chen J; You SJ; Dai J; Xia R; Gao RL
    Chin Med J (Engl); 2011 Mar; 124(6):845-50. PubMed ID: 21518590
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemic immune inflammation index and its implication on in-stent restenosis among patients with acute coronary syndrome.
    Ösken A; Polat F; Çakir B; Zengin A; Çalik AN; Ünal Dayi Ş; Çam N
    Coron Artery Dis; 2024 May; 35(3):209-214. PubMed ID: 38180335
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Do pre-procedural laboratory parameters predict drug-eluting stent restenosis?
    Tanındı A; Ekici B; Töre HF
    Turk Kardiyol Dern Ars; 2015 Jul; 43(5):457-64. PubMed ID: 26148078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials.
    Doi H; Maehara A; Mintz GS; Yu A; Wang H; Mandinov L; Popma JJ; Ellis SG; Grube E; Dawkins KD; Weissman NJ; Turco MA; Ormiston JA; Stone GW
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1269-75. PubMed ID: 20129555
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In-stent restenosis after revascularization of myocardium with drug-eluting stents is accompanied by elevated level of blood plasma eosinophil cationic protein.
    Gabbasov ZA; Kozlov SG; Imaeva AE; Saburova OS; Zykov KA; Masenko VP; Smirnov VN
    Can J Physiol Pharmacol; 2011 Jun; 89(6):413-8. PubMed ID: 21751895
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of Gene Polymorphisms/Haplotypes and Plasma Level of TGF-β1 in Susceptibility to In-Stent Restenosis Following Coronary Implantation of Bare Metal Stent in Chinese Han Patients.
    Chen HJ; Mo N; Zhang YF; Su GZ; Wu HD; Pei F
    Int Heart J; 2018 Jan; 59(1):161-169. PubMed ID: 29332922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
    Richardt G; Leschke M; Abdel-Wahab M; Toelg R; El-Mawardy M; Serruys PW; Silber S; Windecker S; Belardi JA; Neumann FJ; Widimsky P; ;
    JACC Cardiovasc Interv; 2013 Sep; 6(9):905-13. PubMed ID: 23954063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.